LSD1-targeted Therapy-a Multi-purpose Key to Unlock Immunotherapy in Small Cell Lung Cancer

Overview

Journal Transl Lung Cancer Res

Date 2023 Jul 10

PMID 37425423

Authors

Martin Sattler

Ravi Salgia

Affiliations

Soon will be listed here.

Citing Articles

Predictive Signatures for Responses to Checkpoint Blockade in Small-Cell Lung Cancer in Second-Line Therapy Do Not Predict Responses in First-Line Patients.

Thompson J, Tilsed C, Davis C, Gupta A, Melidosian B, Sun C Cancers (Basel). 2024; 16(16).

PMID: 39199568 PMC: 11353197. DOI: 10.3390/cancers16162795.

References

Vanneman M, Dranoff G . Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012; 12(4):237-51. PMC: 3967236. DOI: 10.1038/nrc3237. View

Gay C, Stewart C, Park E, Diao L, Groves S, Heeke S . Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021; 39(3):346-360.e7. PMC: 8143037. DOI: 10.1016/j.ccell.2020.12.014. View

Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K . Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022; 7(1):95. PMC: 8948217. DOI: 10.1038/s41392-022-00934-y. View

Salgia R, Mambetsariev I, Hewelt B, Achuthan S, Li H, Poroyko V . Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. Oncotarget. 2018; 9(40):26226-26242. PMC: 5995226. DOI: 10.18632/oncotarget.25360. View

Hiatt J, Sandborg H, Garrison S, Arnold H, Liao S, Norton J . Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing. Clin Cancer Res. 2022; 28(20):4551-4564. PMC: 9844673. DOI: 10.1158/1078-0432.CCR-22-1128. View

Gong J, Salgia R . Managing Patients With Relapsed Small-Cell Lung Cancer. J Oncol Pract. 2018; 14(6):359-366. PMC: 6002253. DOI: 10.1200/JOP.18.00204. View

Augert A, Eastwood E, Ibrahim A, Wu N, Grunblatt E, Basom R . Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition. Sci Signal. 2019; 12(567). PMC: 6530478. DOI: 10.1126/scisignal.aau2922. View

Rudin C, Awad M, Navarro A, Gottfried M, Peters S, Csoszi T . Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020; 38(21):2369-2379. PMC: 7474472. DOI: 10.1200/JCO.20.00793. View

Goldman J, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D . Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2020; 22(1):51-65. DOI: 10.1016/S1470-2045(20)30539-8. View

10.

Roper N, Velez M, Chiappori A, Kim Y, Wei J, Sindiri S . Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer. Nat Commun. 2021; 12(1):3880. PMC: 8222224. DOI: 10.1038/s41467-021-24164-y. View

11.

Nguyen E, Taniguchi H, Chan J, Zhan Y, Chen X, Qiu J . Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC. J Thorac Oncol. 2022; 17(8):1014-1031. PMC: 9357096. DOI: 10.1016/j.jtho.2022.05.014. View

12.

Sprussel A, Schulte J, Weber S, Necke M, Handschke K, Thor T . Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. Leukemia. 2012; 26(9):2039-51. DOI: 10.1038/leu.2012.157. View

13.

Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser M, Miaou E, Singhal S . Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Mol Cancer Ther. 2021; 20(10):1820-1835. PMC: 8722383. DOI: 10.1158/1535-7163.MCT-21-0013. View

14.

Liu S, Reck M, Mansfield A, Mok T, Scherpereel A, Reinmuth N . Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021; 39(6):619-630. PMC: 8078320. DOI: 10.1200/JCO.20.01055. View

15.

Byers L, Rudin C . Small cell lung cancer: where do we go from here?. Cancer. 2014; 121(5):664-72. PMC: 5497465. DOI: 10.1002/cncr.29098. View

16.

Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G . Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies. Cancer. 2022; 128(17):3185-3195. PMC: 9540525. DOI: 10.1002/cncr.34366. View

17.

Ho W, Wang H, Maggio D, Kovach J, Zhang Q, Song Q . Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Nat Commun. 2018; 9(1):2126. PMC: 5974350. DOI: 10.1038/s41467-018-04425-z. View

18.

Jotatsu T, Yagishita S, Tajima K, Takahashi F, Mogushi K, Hidayat M . LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer. Biochem Biophys Rep. 2017; 9:86-94. PMC: 5614583. DOI: 10.1016/j.bbrep.2016.11.015. View